Radiology’s Fight Against Prior Authorization Delays
ACR is leading national efforts to make prior authorization more efficient and clinically appropriate while reducing the administrative burden and supporting national legislation.
Read moreMain Content
ACR Recommends Tariff Deferrals for Contrast Media
ACR also recommends tariff Deferrals for Radiopharmaceuticals
May 15, 2025
The American College of Radiology® (ACR®) filed comments May 7, with the U.S. Department of Commerce recommending that contrast media and radiopharmaceuticals be excluded or deferred from tariff impacts until greater domestic supplies are available.
ACR’s comments were in response to a request for comments regarding Section 232 national security investigation of pharmaceuticals and ingredients issued by Commerce’s Bureau of Industry and Security (BIS). Section 232 allows the imposition of tariffs on imports that threaten national security. Pharmaceuticals and pharmaceutical ingredients are among several topics being considered by BIS.
The College indicated that contrast media and radiopharmaceuticals are integral components of medical procedures administered by qualified healthcare providers, often without alternative products, and should therefore be excluded or deferred.
For questions, contact Michael Peters, ACR Senior Director, Government Affairs.
Related ACR News
ACR Supports Medicaid Coverage of Lung Cancer Screening
ACR-backed bill would mandate Medicaid lung cancer screening, expand cessation coverage, ban prior auth—aiming to save lives and reduce disparities.
Read morePatient-Centered Imaging Care Led by Radiologists
ACR helps its state chapters fight scope of practice expansion, such as helping to oppose bills in state legislatures that would allow non-physicians to practice independently.
Read more